Cardiovascular therapeutics · 2025
Role of Macrophage Phagocytosis as Predictive Marker of the Prevalence of Coronary Heart Disease and Acute Coronary Syndromes.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Wang Yuming, Zhou Wenjing, Zhou Qinyi, Du Changqing, Tang Yimin, Zhu Kefu
Аннотация
BACKGROUND: Atherosclerotic cardiovascular disease (ASCVD) pathogenesis is closely associated with macrophages. This study sought to explore the role of phagocytosis by monocyte-derived macrophages (MDMs) in the blood in the context of coronary heart disease (CHD) and acute coronary syndromes (ACSs).
METHODS: This study employed a matched case-control design. Individuals with suspected CHD were recruited and allocated to a control cohort or a CHD cohort, with the latter further stratified into stable angina pectoris and ACS subgroups according to clinical diagnoses. Clinical data were collected, MDMs were isolated, and macrophage phagocytic activity was evaluated using fluorescent-labeled latex microspheres.
RESULTS: Macrophage phagocytic rates were significantly reduced in the CHD group relative to the control group, with further decreases observed in the ACS subgroup. Multivariable linear regression revealed that age, low-density lipoprotein cholesterol (LDL-C), high-sensitivity C-reactive protein (hs-CRP), and fibrinogen were independently and negatively correlated with macrophage phagocytic rates. Multivariable analyses suggested that diminished macrophage phagocytic rates were linked to an elevated risk of both CHD and ACS. Receiver operating characteristic (ROC) curve analysis identified the optimal cutoff values of macrophage phagocytic rates for predicting CHD and ACS as 62.6% and 63.4%, respectively, with the area under the curves (AUCs) measured at 0.679 and 0.669.
CONCLUSIONS: Macrophage phagocytic activity is reduced in CHD patients, particularly in those with ACS. Diminished macrophage phagocytic function is linked to CHD and ACS. Macrophage phagocytosis could act as a protective biomarker in CHD and ACS, providing new insights into the pathophysiology of ASCVD.
METHODS: This study employed a matched case-control design. Individuals with suspected CHD were recruited and allocated to a control cohort or a CHD cohort, with the latter further stratified into stable angina pectoris and ACS subgroups according to clinical diagnoses. Clinical data were collected, MDMs were isolated, and macrophage phagocytic activity was evaluated using fluorescent-labeled latex microspheres.
RESULTS: Macrophage phagocytic rates were significantly reduced in the CHD group relative to the control group, with further decreases observed in the ACS subgroup. Multivariable linear regression revealed that age, low-density lipoprotein cholesterol (LDL-C), high-sensitivity C-reactive protein (hs-CRP), and fibrinogen were independently and negatively correlated with macrophage phagocytic rates. Multivariable analyses suggested that diminished macrophage phagocytic rates were linked to an elevated risk of both CHD and ACS. Receiver operating characteristic (ROC) curve analysis identified the optimal cutoff values of macrophage phagocytic rates for predicting CHD and ACS as 62.6% and 63.4%, respectively, with the area under the curves (AUCs) measured at 0.679 and 0.669.
CONCLUSIONS: Macrophage phagocytic activity is reduced in CHD patients, particularly in those with ACS. Diminished macrophage phagocytic function is linked to CHD and ACS. Macrophage phagocytosis could act as a protective biomarker in CHD and ACS, providing new insights into the pathophysiology of ASCVD.